{"name":"Ospedale Misericordia e Dolce","slug":"ospedale-misericordia-e-dolce","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Hydration plus N-acetylcisteine","genericName":"Hydration plus N-acetylcisteine","slug":"hydration-plus-n-acetylcisteine","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"atorvastatin and clopidogrel","genericName":"atorvastatin and clopidogrel","slug":"atorvastatin-and-clopidogrel","indication":"Secondary prevention of cardiovascular events in patients with acute coronary syndrome","status":"marketed"}]}],"pipeline":[{"name":"Hydration plus N-acetylcisteine","genericName":"Hydration plus N-acetylcisteine","slug":"hydration-plus-n-acetylcisteine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"atorvastatin and clopidogrel","genericName":"atorvastatin and clopidogrel","slug":"atorvastatin-and-clopidogrel","phase":"marketed","mechanism":"This combination reduces cholesterol levels and prevents blood clots by inhibiting HMG-CoA reductase and platelet aggregation, respectively.","indications":["Secondary prevention of cardiovascular events in patients with acute coronary syndrome","Prevention of stent thrombosis following percutaneous coronary intervention","Reduction of cardiovascular risk in patients with established coronary artery disease"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}